AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00709826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: Gemcitabine: per package insert.
Study NCT00709826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo: 100 mg tablets, 400 mg/day
Study NCT04428489 — intervention group
Intervention type: OTHER
Intervention: Observation and necessary supportive care
Description: For patients with ICUS and CCUS, necessary supportive care could be given. No addtitional treatment is administrated.
Study NCT00709826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib - per package insert.
Study NCT00709826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib - per package insert.
Study NCT00709826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricoxib
Description: apricoxib: 100mg tablets, given orally
Study NCT04172090 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Normal physical activity and standard energy intake
Study NCT04172090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIT+E
Description: Reduced physical activity and standard energy intake
Study NCT04172090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIT=E
Description: Reduced physical activity and reduced energy intake
Study NCT03631927 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation
Study NCT03856957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff colonoscopy
Description: Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).
Study NCT03856957 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: colonoscopy without endocuff
Study NCT03065179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/Ipilimumab
Description: IV immunotherapy
Study NCT03065179 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT will be delivered in conjunction with immunotherapy
Study NCT03502512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03502512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive Surgery
Description: Undergo reconstructive surgery with REVOLVE technique
Study NCT03502512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive Surgery
Description: Undergo reconstructive surgery with PureGraft technique
Study NCT04159090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F18-PSMA
Description: Patients with moderate or high risk of prostate cancer
Study NCT03294993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound assess
Description: The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
Study NCT01973257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: imaging diagnostics
Study NCT04222829 — intervention group
Intervention type: PROCEDURE
Intervention: Megadose Shinbaro Pharmacopuncture
Description: Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases.
Study NCT02850848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entigin Film Coated Tablet 0.5mg
Study NCT02850848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Baraclude 0.5mg Tablets
Study NCT04023084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole
Description: Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
Study NCT00138216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00138216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT02115386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: supplied in 150 mg capsules to be taken orally
Study NCT00138216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT02979756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decentralized GDM screening and initial management
Description: Screening for GDM and initialization of nutritional therapy at the first level of care
Study NCT00623831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixed bacterial vaccine
Description: MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
Study NCT01800721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SNAP
Description: Behavioral: SNAP 7 group sessions, and 1 individual session
Study NCT01800721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SNAP Control
Description: Behavioral: SNAP control 7 group sessions
Study NCT03124459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
Study NCT03124459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Recombinant fusion protein or buffer solution
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study NCT01268085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation Alert
Description: A radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part
Study NCT01268085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control with no inverention
Study NCT03190005 — intervention group
Intervention type: DRUG
Intervention: clopidogrel
Description: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
Study NCT03190005 — intervention group
Intervention type: DRUG
Intervention: Placebos
Description: no medication, healthy subjects.
Study NCT01880814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
Study NCT01880814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver-Child Treatment
Description: Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
Study NCT00252720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan
Description: 32 mg oral tablet
Study NCT00578552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
Study NCT00578552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin - 1800 mg/day
Description: gabapentin - 1800 mg/day for 12 weeks.
Study NCT00578552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin - 2700 mg/day
Description: gabapentin - 2700 mg/day for 12 weeks.
Study NCT03171285 — intervention group
Intervention type: OTHER
Intervention: Less than 35 years old
Description: Clinical and laboratory evaluations
Study NCT03171285 — intervention group
Intervention type: OTHER
Intervention: Greater than or equal to 35 years
Description: Clinical and laboratory evaluations
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT01827163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01827163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
Study NCT01827163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study NCT01827163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
Study NCT00207688 — intervention group
Intervention type: DRUG
Intervention: Infliximab 5 mg/kg
Description: Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
Study NCT00207688 — intervention group
Intervention type: DRUG
Intervention: Infliximab 10 mg/kg
Description: Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
Study NCT00207688 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
Study NCT03723993 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inflated cuff
Description: After patient being draped, applying cuff inflation will be done to the upper arm not having the arterial line inserted of about 200 mmHg or 15 mmHg above patient's systolic pressure 3 cycles 5 minutes each followed by 5 minutes of pressure relieve
Study NCT03723993 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non inflated cuff
Description: non inflated cuff around the arm for the control group
Study NCT00723476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Centered Advanced Care Planning (FCACP) sessions
Description: FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
Study NCT00723476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education control sessions
Description: Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
Study NCT00584025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: 100 - 500mg IV q 15 min
Study NCT00584025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
Study NCT01486147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual nutrient profiling tool
Description: Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.
Study NCT01486147 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrient ratings table
Description: Showed nutrition information and had to match to fiber and protein ratings from a table.
Study NCT00352820 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Recorded face-to-face session.
Study NCT00352820 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Written survey lasting approximately 30 minutes.
Study NCT00766168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HDS HI 1.54; pahrifocon A
Description: Contact Lens
Study NCT05480345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Impedance cardiography
Description: Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
Study NCT00766168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FluoroPerm 30 RGP; paflufocon C
Description: Contact lens daily wear
Study NCT02118532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
Description: IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic
Study NCT03944447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis, Medical
Description: Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
Study NCT02358317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Game Motor Training
Study NCT03944447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RYAH-Medtech Inhaler
Description: Our research study will involve incorporation of RYAH-Medtech company's devices into our protocols. They have an inhaler and a transdermal patch for both hemp-derived CBD and cannabis. RYAH has developed an integrated phone app for tracking product use and patient response. They are currently involved in clinical trials in Europe. OMNI Medical will integrate the partner with RYAH device for several reasons. Primary goals will involve using their integrated smart phone app to collect and secure large quantities of data. Secondary goals will include FDA approval as a medical device. The specific cannabis strain will be tracked using scannable QR codes programed into the smart phone app. This will allow us to track patient feedback and capture data on usage. OMNI Medical will have patients use RYAH's products as part of and FDA Investigational Device Exemption, which requires an IRB. Use of the devices would be completely voluntary by study participants.
Study NCT03541941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
Study NCT03541941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
Study NCT03541941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
Study NCT03541941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block
Study NCT01393366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telephone Intervention
Description: Only for arm AMA, patient will have one phone every week to evaluate physical conditions.
Study NCT01393366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Practice
Description: None, only usual practice.
Study NCT03974685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)
Description: Single dose
Study NCT00794547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.
Study NCT00794547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
Study NCT01688609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO
Study NCT01688609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01688609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT01688609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo lumpectomy or mastectomy
Study NCT01688609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01688609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00318812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heme Iron Polypeptide (Proferrin)
Description: Heme iron polypeptide 11mg po tid for 6 months
Study NCT00318812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose (Venofer)
Description: Iron sucrose infusion IV q month x 6 months
Study NCT02358317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sedentary Video Game Training
Study NCT01883856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone plate Ahmed Glaucoma Valve (Model FP7)
Description: This intervention is conducted as a surgical intervention.
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Study NCT00430118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT02036918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sipuleucel-T
Study NCT02036918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Study NCT01883856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porous Plate Ahmed Glaucoma Valve (Model M4)
Description: This intervention is conducted as a surgical intervention.
Study NCT04391985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF plus (OBV/PTV/r) plus RBV
Description: They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
Study NCT03446144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-FB-Lrx
Description: Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70
Study NCT03446144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sterline saline 0.9%)
Description: Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
Study NCT00603642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously administered, once a week, for 12 weeks
Study NCT00603642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 531
Description: Subcutaneously administered, once a week, for 12 weeks